•
Jun 30, 2022
Zomedica Q2 2022 Earnings Report
Announced second quarter 2022 financial results with $4.2 million of revenue, 71% gross margin and $186.8 million in cash.
Key Takeaways
Zomedica reported a 51% increase in revenue compared to the previous year, with total revenue reaching $4.2 million. The company's gross margin was 71%, and it ended the quarter with $186.8 million in cash and cash equivalents. Net loss for the quarter was $5.3 million, or $0.005 per share.
Total revenue for the second quarter 2022 was $4.2 million, compared to $16,000 in the second quarter of 2021.
Gross margin was 71%.
TRUFORMA® product revenue was $92,000 in the second quarter of 2022, an increase of 486% over second quarter 2021 revenue of $16,000.
PulseVet® revenue was $4.2 million in the second quarter 2022, an increase of 48% over its second quarter 2021 revenue of $2.8 million as a standalone company.